ES2204171T3 - Derivados de furopiridina y su utilizacion terapeutica. - Google Patents
Derivados de furopiridina y su utilizacion terapeutica.Info
- Publication number
- ES2204171T3 ES2204171T3 ES99955472T ES99955472T ES2204171T3 ES 2204171 T3 ES2204171 T3 ES 2204171T3 ES 99955472 T ES99955472 T ES 99955472T ES 99955472 T ES99955472 T ES 99955472T ES 2204171 T3 ES2204171 T3 ES 2204171T3
- Authority
- ES
- Spain
- Prior art keywords
- pyridine
- carboxylic acid
- amide
- alkyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 186
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 39
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 12
- 229910002091 carbon monoxide Inorganic materials 0.000 claims abstract description 9
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 7
- 230000005764 inhibitory process Effects 0.000 claims abstract description 5
- -1 heterocyclocarbonyl Chemical group 0.000 claims description 60
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims description 40
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 29
- 150000001408 amides Chemical class 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 21
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 13
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 12
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 9
- HECKHHKBGHBFRI-UHFFFAOYSA-N 2-ethyl-7-methoxyfuro[2,3-c]pyridine-4-carboxylic acid Chemical compound C1=NC(OC)=C2OC(CC)=CC2=C1C(O)=O HECKHHKBGHBFRI-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 7
- YGQBWCUTYFBTLH-UHFFFAOYSA-N 7-(difluoromethoxy)-2-ethylfuro[2,3-c]pyridine-4-carboxylic acid Chemical compound C1=NC(OC(F)F)=C2OC(CC)=CC2=C1C(O)=O YGQBWCUTYFBTLH-UHFFFAOYSA-N 0.000 claims description 6
- JBHMSHKWKKUOBI-UHFFFAOYSA-N 7-methoxy-2-(methoxymethyl)furo[2,3-c]pyridine-4-carboxylic acid Chemical compound C1=NC(OC)=C2OC(COC)=CC2=C1C(O)=O JBHMSHKWKKUOBI-UHFFFAOYSA-N 0.000 claims description 6
- GAYIUIZSLAYZQD-UHFFFAOYSA-N 7-methoxy-2-pyridin-3-ylfuro[2,3-c]pyridine-4-carboxylic acid Chemical compound O1C=2C(OC)=NC=C(C(O)=O)C=2C=C1C1=CC=CN=C1 GAYIUIZSLAYZQD-UHFFFAOYSA-N 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- UUZUZXKIHFCSMM-UHFFFAOYSA-N 2-acetyl-7-methoxyfuro[2,3-c]pyridine-4-carboxylic acid Chemical compound COC1=NC=C(C(O)=O)C2=C1OC(C(C)=O)=C2 UUZUZXKIHFCSMM-UHFFFAOYSA-N 0.000 claims description 5
- WPLOHFKEAQILDY-UHFFFAOYSA-N 7-methoxy-2-(oxan-4-yl)furo[2,3-c]pyridine-4-carboxylic acid Chemical compound O1C=2C(OC)=NC=C(C(O)=O)C=2C=C1C1CCOCC1 WPLOHFKEAQILDY-UHFFFAOYSA-N 0.000 claims description 5
- FJACYEGKPUDXGT-UHFFFAOYSA-N 7-methoxy-2-(oxolan-3-yl)furo[2,3-c]pyridine-4-carboxylic acid Chemical compound O1C=2C(OC)=NC=C(C(O)=O)C=2C=C1C1CCOC1 FJACYEGKPUDXGT-UHFFFAOYSA-N 0.000 claims description 5
- IVTZZXUOAXLCLE-UHFFFAOYSA-N N-(3,5-dichloropyridin-4-yl)pyridine-4-carboxamide Chemical compound ClC=1C=NC=C(C=1NC(=O)C1=CC=NC=C1)Cl IVTZZXUOAXLCLE-UHFFFAOYSA-N 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 208000007451 chronic bronchitis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000003979 eosinophil Anatomy 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 3
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 3
- MWWJOVIPSZWFRA-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-7-methoxy-2-(oxan-4-yl)furo[2,3-c]pyridine-4-carboxamide Chemical compound C1=2C=C(C3CCOCC3)OC=2C(OC)=NC=C1C(=O)NC1=C(Cl)C=NC=C1Cl MWWJOVIPSZWFRA-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- KBWZNINGQMYRLL-UHFFFAOYSA-N 2-ethyl-7-methoxy-n-(2,4,6-trifluorophenyl)furo[2,3-c]pyridine-4-carboxamide Chemical compound C1=NC(OC)=C2OC(CC)=CC2=C1C(=O)NC1=C(F)C=C(F)C=C1F KBWZNINGQMYRLL-UHFFFAOYSA-N 0.000 claims description 2
- OVRQXTOABUYRBP-UHFFFAOYSA-N 2-ethyl-7-methoxy-n-(3-methoxypyridin-4-yl)furo[2,3-c]pyridine-4-carboxamide Chemical compound C1=NC(OC)=C2OC(CC)=CC2=C1C(=O)NC1=CC=NC=C1OC OVRQXTOABUYRBP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- HTHCTEPBVMVZEO-UHFFFAOYSA-N 7-(difluoromethoxy)-2-ethyl-n-[2-(trifluoromethyl)phenyl]furo[2,3-c]pyridine-4-carboxamide Chemical compound C1=NC(OC(F)F)=C2OC(CC)=CC2=C1C(=O)NC1=CC=CC=C1C(F)(F)F HTHCTEPBVMVZEO-UHFFFAOYSA-N 0.000 claims description 2
- AHYNSZBGYURKIP-UHFFFAOYSA-N 7-(difluoromethoxy)-n-(3,5-dimethyl-1,2-oxazol-4-yl)-2-ethylfuro[2,3-c]pyridine-4-carboxamide Chemical compound C1=NC(OC(F)F)=C2OC(CC)=CC2=C1C(=O)NC=1C(C)=NOC=1C AHYNSZBGYURKIP-UHFFFAOYSA-N 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 2
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 206010022562 Intermittent claudication Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 230000002917 arthritic effect Effects 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- CCAJLYNVQAPNDK-UHFFFAOYSA-N furo[2,3-c]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CN=CC2=C1C=CO2 CCAJLYNVQAPNDK-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- BGKKBKFAZIQCJN-UHFFFAOYSA-N n-(2,6-dichloro-4-cyanophenyl)-7-(difluoromethoxy)-2-ethylfuro[2,3-c]pyridine-4-carboxamide Chemical compound C1=NC(OC(F)F)=C2OC(CC)=CC2=C1C(=O)NC1=C(Cl)C=C(C#N)C=C1Cl BGKKBKFAZIQCJN-UHFFFAOYSA-N 0.000 claims description 2
- NMHMCFQCKWXEEX-UHFFFAOYSA-N n-(4-cyano-2-methylpyrazol-3-yl)-7-(difluoromethoxy)-2-ethylfuro[2,3-c]pyridine-4-carboxamide Chemical compound C1=NC(OC(F)F)=C2OC(CC)=CC2=C1C(=O)NC1=C(C#N)C=NN1C NMHMCFQCKWXEEX-UHFFFAOYSA-N 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- FMOKVKNOLGASDQ-UHFFFAOYSA-N 2-acetyl-7-methoxy-n-(3-methylpyridin-4-yl)furo[2,3-c]pyridine-4-carboxamide Chemical compound C1=2C=C(C(C)=O)OC=2C(OC)=NC=C1C(=O)NC1=CC=NC=C1C FMOKVKNOLGASDQ-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 231100000284 endotoxic Toxicity 0.000 claims 1
- 230000002346 endotoxic effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- DBXFIMHDCBOHHB-UHFFFAOYSA-N n-(2,6-dichloro-4-cyanophenyl)-2-ethyl-7-methoxyfuro[2,3-c]pyridine-4-carboxamide Chemical compound C1=NC(OC)=C2OC(CC)=CC2=C1C(=O)NC1=C(Cl)C=C(C#N)C=C1Cl DBXFIMHDCBOHHB-UHFFFAOYSA-N 0.000 claims 1
- UWLDHAFCBFXQMX-UHFFFAOYSA-N n-(2,6-difluorophenyl)-2-ethyl-7-methoxyfuro[2,3-c]pyridine-4-carboxamide Chemical compound C1=NC(OC)=C2OC(CC)=CC2=C1C(=O)NC1=C(F)C=CC=C1F UWLDHAFCBFXQMX-UHFFFAOYSA-N 0.000 claims 1
- JESCGEWQDVNBSE-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-ethyl-7-methoxyfuro[2,3-c]pyridine-4-carboxamide Chemical compound C1=NC(OC)=C2OC(CC)=CC2=C1C(=O)NC1=C(Cl)C=NC=C1Cl JESCGEWQDVNBSE-UHFFFAOYSA-N 0.000 claims 1
- CMQJWHDXTPYSNM-UHFFFAOYSA-N n-(5-cyanopyrimidin-4-yl)-2-ethyl-7-methoxyfuro[2,3-c]pyridine-4-carboxamide Chemical compound C1=NC(OC)=C2OC(CC)=CC2=C1C(=O)NC1=NC=NC=C1C#N CMQJWHDXTPYSNM-UHFFFAOYSA-N 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000009967 tasteless effect Effects 0.000 claims 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 claims 1
- 230000009772 tissue formation Effects 0.000 claims 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract description 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000962 organic group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 263
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 224
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 156
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 144
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 105
- 238000004809 thin layer chromatography Methods 0.000 description 76
- 239000007787 solid Substances 0.000 description 68
- 238000000746 purification Methods 0.000 description 57
- 239000000047 product Substances 0.000 description 54
- 238000004440 column chromatography Methods 0.000 description 53
- 239000000377 silicon dioxide Substances 0.000 description 52
- 239000000543 intermediate Substances 0.000 description 48
- 239000000203 mixture Substances 0.000 description 48
- 239000002904 solvent Substances 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- 235000019341 magnesium sulphate Nutrition 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 150000003254 radicals Chemical class 0.000 description 17
- 239000002585 base Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 238000001665 trituration Methods 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 238000010561 standard procedure Methods 0.000 description 12
- 238000001819 mass spectrum Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
- 239000012312 sodium hydride Substances 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- DVILKHNLGIDKHW-UHFFFAOYSA-N 7-methoxyfuro[2,3-c]pyridine Chemical compound COC1=NC=CC2=C1OC=C2 DVILKHNLGIDKHW-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000002168 alkylating agent Substances 0.000 description 8
- 229940100198 alkylating agent Drugs 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 4
- XEFGYHCLUPWFSK-UHFFFAOYSA-N 3,5-dichloro-1-hydroxypyridin-4-imine Chemical compound ON1C=C(Cl)C(=N)C(Cl)=C1 XEFGYHCLUPWFSK-UHFFFAOYSA-N 0.000 description 4
- ISIQAMHROGZHOV-UHFFFAOYSA-N 3,5-dichloropyridin-4-amine Chemical compound NC1=C(Cl)C=NC=C1Cl ISIQAMHROGZHOV-UHFFFAOYSA-N 0.000 description 4
- OATQEIAUQAVLFI-UHFFFAOYSA-N 7-methoxy-2-(4-methoxy-1-methylpiperidin-4-yl)furo[2,3-c]pyridine-4-carboxylic acid Chemical compound O1C=2C(OC)=NC=C(C(O)=O)C=2C=C1C1(OC)CCN(C)CC1 OATQEIAUQAVLFI-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 150000002923 oximes Chemical class 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- DZJMYCPMJJJNBQ-UHFFFAOYSA-N 1-(4-bromo-7-methoxyfuro[2,3-c]pyridin-2-yl)ethanone Chemical compound COC1=NC=C(Br)C2=C1OC(C(C)=O)=C2 DZJMYCPMJJJNBQ-UHFFFAOYSA-N 0.000 description 3
- OGCJPLPWXXFNAO-UHFFFAOYSA-N 2-(1,1-dimethoxyethyl)-7-methoxyfuro[2,3-c]pyridine-4-carboxylic acid Chemical compound COC1=NC=C(C(O)=O)C2=C1OC(C(C)(OC)OC)=C2 OGCJPLPWXXFNAO-UHFFFAOYSA-N 0.000 description 3
- VGJLGPCXUGIXRQ-UHFFFAOYSA-N 3-methylpyridin-4-amine Chemical compound CC1=CN=CC=C1N VGJLGPCXUGIXRQ-UHFFFAOYSA-N 0.000 description 3
- NDTNVCCDQAOBSZ-UHFFFAOYSA-N 4-amino-3-chloro-5-methylbenzonitrile Chemical compound CC1=CC(C#N)=CC(Cl)=C1N NDTNVCCDQAOBSZ-UHFFFAOYSA-N 0.000 description 3
- NIQGPIGASRWXIV-UHFFFAOYSA-N 4-bromo-2-ethyl-7-methoxyfuro[2,3-c]pyridine Chemical compound C1=NC(OC)=C2OC(CC)=CC2=C1Br NIQGPIGASRWXIV-UHFFFAOYSA-N 0.000 description 3
- NIHGMXXHBXKXQI-UHFFFAOYSA-N 4-bromo-7-methoxy-2-(4-methoxypiperidin-4-yl)furo[2,3-c]pyridine Chemical compound O1C=2C(OC)=NC=C(Br)C=2C=C1C1(OC)CCNCC1 NIHGMXXHBXKXQI-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- 230000006433 tumor necrosis factor production Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- YSXNZROPRIQXLE-UHFFFAOYSA-N (4-nitrophenyl) 2-(1,1-dimethoxyethyl)-7-methoxyfuro[2,3-c]pyridine-4-carboxylate Chemical compound C1=2C=C(C(C)(OC)OC)OC=2C(OC)=NC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 YSXNZROPRIQXLE-UHFFFAOYSA-N 0.000 description 2
- ORQWYNVHFBUBDP-UHFFFAOYSA-N (4-nitrophenyl) 2-acetyl-7-methoxyfuro[2,3-c]pyridine-4-carboxylate Chemical compound C1=2C=C(C(C)=O)OC=2C(OC)=NC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 ORQWYNVHFBUBDP-UHFFFAOYSA-N 0.000 description 2
- NBMRMZBDGQATBD-UHFFFAOYSA-N (7-methoxyfuro[2,3-c]pyridin-2-yl)methanol Chemical compound COC1=NC=CC2=C1OC(CO)=C2 NBMRMZBDGQATBD-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HSKSWSSWMWJQJG-UHFFFAOYSA-N 1-(7-methoxyfuro[2,3-c]pyridin-2-yl)ethanol Chemical compound COC1=NC=CC2=C1OC(C(C)O)=C2 HSKSWSSWMWJQJG-UHFFFAOYSA-N 0.000 description 2
- CVYYDXZUAKVMLR-UHFFFAOYSA-N 1-(7-methoxyfuro[2,3-c]pyridin-2-yl)ethanone Chemical compound COC1=NC=CC2=C1OC(C(C)=O)=C2 CVYYDXZUAKVMLR-UHFFFAOYSA-N 0.000 description 2
- IYOFXOPSKBTQLD-UHFFFAOYSA-N 2-(1,1-dimethoxyethyl)-7-methoxy-n-(3-methylpyridin-4-yl)furo[2,3-c]pyridine-4-carboxamide Chemical compound C1=2C=C(C(C)(OC)OC)OC=2C(OC)=NC=C1C(=O)NC1=CC=NC=C1C IYOFXOPSKBTQLD-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- QSTVUSIFKBIKCZ-UHFFFAOYSA-N 2-bromo-7-methoxyfuro[2,3-c]pyridine Chemical compound COC1=NC=CC2=C1OC(Br)=C2 QSTVUSIFKBIKCZ-UHFFFAOYSA-N 0.000 description 2
- AWFFWTDUPVHHBB-UHFFFAOYSA-N 2-ethyl-7-methoxyfuro[2,3-c]pyridine Chemical compound C1=NC(OC)=C2OC(CC)=CC2=C1 AWFFWTDUPVHHBB-UHFFFAOYSA-N 0.000 description 2
- FFDBUEMOEHXVTA-UHFFFAOYSA-N 4-(4-bromo-7-methoxyfuro[2,3-c]pyridin-2-yl)-4-methoxypiperidine-1-carboxylic acid Chemical compound O1C=2C(OC)=NC=C(Br)C=2C=C1C1(OC)CCN(C(O)=O)CC1 FFDBUEMOEHXVTA-UHFFFAOYSA-N 0.000 description 2
- XVFVWQVRRBYRTA-UHFFFAOYSA-N 4-(7-methoxyfuro[2,3-c]pyridin-2-yl)oxan-4-ol Chemical compound O1C=2C(OC)=NC=CC=2C=C1C1(O)CCOCC1 XVFVWQVRRBYRTA-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- COFNCCWGWXFACE-UHFFFAOYSA-N 4-amino-3,5-dichlorobenzonitrile Chemical compound NC1=C(Cl)C=C(C#N)C=C1Cl COFNCCWGWXFACE-UHFFFAOYSA-N 0.000 description 2
- IKKZQHNHCOPYNW-UHFFFAOYSA-N 4-bromo-2-(1,1-dimethoxyethyl)-7-methoxyfuro[2,3-c]pyridine Chemical compound COC1=NC=C(Br)C2=C1OC(C(C)(OC)OC)=C2 IKKZQHNHCOPYNW-UHFFFAOYSA-N 0.000 description 2
- HHZOEIRGIVOUCQ-UHFFFAOYSA-N 4-bromo-2-ethyl-6h-furo[2,3-c]pyridin-7-one Chemical compound BrC1=CNC(=O)C2=C1C=C(CC)O2 HHZOEIRGIVOUCQ-UHFFFAOYSA-N 0.000 description 2
- LBNCDIDBOWQGCC-UHFFFAOYSA-N 4-bromo-7-(difluoromethoxy)-2-ethylfuro[2,3-c]pyridine Chemical compound C1=NC(OC(F)F)=C2OC(CC)=CC2=C1Br LBNCDIDBOWQGCC-UHFFFAOYSA-N 0.000 description 2
- GZUNZKSORQVRRC-UHFFFAOYSA-N 4-bromo-7-methoxy-2-(methoxymethyl)furo[2,3-c]pyridine Chemical compound C1=NC(OC)=C2OC(COC)=CC2=C1Br GZUNZKSORQVRRC-UHFFFAOYSA-N 0.000 description 2
- GWHXZEAIBWZFDZ-UHFFFAOYSA-N 4-bromo-7-methoxy-2-(oxan-4-yl)furo[2,3-c]pyridine Chemical compound O1C=2C(OC)=NC=C(Br)C=2C=C1C1CCOCC1 GWHXZEAIBWZFDZ-UHFFFAOYSA-N 0.000 description 2
- IBPCQGWKJFPVIT-UHFFFAOYSA-N 4-bromo-7-methoxy-2-(oxolan-3-yl)furo[2,3-c]pyridine Chemical compound O1C=2C(OC)=NC=C(Br)C=2C=C1C1CCOC1 IBPCQGWKJFPVIT-UHFFFAOYSA-N 0.000 description 2
- SKAQGBWYUIFKSZ-UHFFFAOYSA-N 4-bromo-7-methoxy-2-pyridin-3-ylfuro[2,3-c]pyridine Chemical compound O1C=2C(OC)=NC=C(Br)C=2C=C1C1=CC=CN=C1 SKAQGBWYUIFKSZ-UHFFFAOYSA-N 0.000 description 2
- PIVBHKRIDYRPJQ-UHFFFAOYSA-N 4-methoxy-4-(7-methoxyfuro[2,3-c]pyridin-2-yl)piperidine-1-carboxylic acid Chemical compound O1C=2C(OC)=NC=CC=2C=C1C1(OC)CCN(C(O)=O)CC1 PIVBHKRIDYRPJQ-UHFFFAOYSA-N 0.000 description 2
- MZFBWODPTSTYAI-UHFFFAOYSA-N 5-amino-1-methylpyrazole-4-carbonitrile Chemical compound CN1N=CC(C#N)=C1N MZFBWODPTSTYAI-UHFFFAOYSA-N 0.000 description 2
- SHSNAKRNZGOTJL-UHFFFAOYSA-N 6h-furo[2,3-c]pyridin-7-one Chemical compound OC1=NC=CC2=C1OC=C2 SHSNAKRNZGOTJL-UHFFFAOYSA-N 0.000 description 2
- JEIKSMFYTXEJJB-UHFFFAOYSA-N 7-methoxy-2-(methoxymethyl)furo[2,3-c]pyridine Chemical compound C1=NC(OC)=C2OC(COC)=CC2=C1 JEIKSMFYTXEJJB-UHFFFAOYSA-N 0.000 description 2
- JYGZLZIIKMFEKK-UHFFFAOYSA-N 7-methoxy-2-(oxan-4-yl)furo[2,3-c]pyridine Chemical compound O1C=2C(OC)=NC=CC=2C=C1C1CCOCC1 JYGZLZIIKMFEKK-UHFFFAOYSA-N 0.000 description 2
- PUIXJSVUCXKSKS-UHFFFAOYSA-N 7-methoxy-2-(oxolan-3-yl)furo[2,3-c]pyridine Chemical compound O1C=2C(OC)=NC=CC=2C=C1C1CCOC1 PUIXJSVUCXKSKS-UHFFFAOYSA-N 0.000 description 2
- LFOBJYMTLLOGGL-UHFFFAOYSA-N 7-methoxy-2-[4-methoxy-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]furo[2,3-c]pyridine-4-carboxylic acid Chemical compound O1C=2C(OC)=NC=C(C(O)=O)C=2C=C1C1(OC)CCN(C(=O)OC(C)(C)C)CC1 LFOBJYMTLLOGGL-UHFFFAOYSA-N 0.000 description 2
- ZWYWPMDGHCEZLT-UHFFFAOYSA-N 7-methoxy-2-pyridin-3-ylfuro[2,3-c]pyridine Chemical compound O1C=2C(OC)=NC=CC=2C=C1C1=CC=CN=C1 ZWYWPMDGHCEZLT-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- YYTMBGZDOXJUSQ-UHFFFAOYSA-N n-(3-chloropyridin-4-yl)pyridine-4-carboxamide Chemical compound ClC1=CN=CC=C1NC(=O)C1=CC=NC=C1 YYTMBGZDOXJUSQ-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000001012 protector Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- NMNROOWPQMQIDN-UHFFFAOYSA-N (4-nitrophenyl) 2-ethyl-7-methoxyfuro[2,3-c]pyridine-4-carboxylate Chemical compound C1=NC(OC)=C2OC(CC)=CC2=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 NMNROOWPQMQIDN-UHFFFAOYSA-N 0.000 description 1
- HQMMPJGIMVTELJ-UHFFFAOYSA-N (4-nitrophenyl) 7-(difluoromethoxy)-2-ethylfuro[2,3-c]pyridine-4-carboxylate Chemical compound C1=NC(OC(F)F)=C2OC(CC)=CC2=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 HQMMPJGIMVTELJ-UHFFFAOYSA-N 0.000 description 1
- FJJLNVOHKNTXDQ-UHFFFAOYSA-N (4-nitrophenyl) 7-methoxy-2-(4-methoxy-1-methylpiperidin-4-yl)furo[2,3-c]pyridine-4-carboxylate Chemical compound C1=2C=C(C3(CCN(C)CC3)OC)OC=2C(OC)=NC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 FJJLNVOHKNTXDQ-UHFFFAOYSA-N 0.000 description 1
- NRWISGTYFLIIQE-UHFFFAOYSA-N (4-nitrophenyl) 7-methoxy-2-(methoxymethyl)furo[2,3-c]pyridine-4-carboxylate Chemical compound C1=NC(OC)=C2OC(COC)=CC2=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 NRWISGTYFLIIQE-UHFFFAOYSA-N 0.000 description 1
- BXHXVGNZWBBHRS-UHFFFAOYSA-N (4-nitrophenyl) 7-methoxy-2-(oxan-4-yl)furo[2,3-c]pyridine-4-carboxylate Chemical compound C1=2C=C(C3CCOCC3)OC=2C(OC)=NC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 BXHXVGNZWBBHRS-UHFFFAOYSA-N 0.000 description 1
- KOKBUYYJGIKLAI-UHFFFAOYSA-N (4-nitrophenyl) 7-methoxy-2-(oxolan-3-yl)furo[2,3-c]pyridine-4-carboxylate Chemical compound C1=2C=C(C3COCC3)OC=2C(OC)=NC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 KOKBUYYJGIKLAI-UHFFFAOYSA-N 0.000 description 1
- RBZSYEKKJWNLAR-UHFFFAOYSA-N (4-nitrophenyl) 7-methoxy-2-pyridin-3-ylfuro[2,3-c]pyridine-4-carboxylate Chemical compound C1=2C=C(C=3C=NC=CC=3)OC=2C(OC)=NC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 RBZSYEKKJWNLAR-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical class C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BJSVKBGQDHUBHZ-UHFFFAOYSA-N 2,4,6-trifluoroaniline Chemical compound NC1=C(F)C=C(F)C=C1F BJSVKBGQDHUBHZ-UHFFFAOYSA-N 0.000 description 1
- ODUZJBKKYBQIBX-UHFFFAOYSA-N 2,6-difluoroaniline Chemical compound NC1=C(F)C=CC=C1F ODUZJBKKYBQIBX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- VBLXCTYLWZJBKA-UHFFFAOYSA-N 2-(trifluoromethyl)aniline Chemical compound NC1=CC=CC=C1C(F)(F)F VBLXCTYLWZJBKA-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- INSUSOZBMWJGDG-UHFFFAOYSA-N 3,5-dimethyl-1,2-oxazol-4-amine Chemical compound CC1=NOC(C)=C1N INSUSOZBMWJGDG-UHFFFAOYSA-N 0.000 description 1
- KULMYOIAOYZBKP-UHFFFAOYSA-N 3-(7-methoxyfuro[2,3-c]pyridin-2-yl)oxolan-3-ol Chemical compound O1C=2C(OC)=NC=CC=2C=C1C1(O)CCOC1 KULMYOIAOYZBKP-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- KJBKPRMEMJKXDV-UHFFFAOYSA-N 3-chloropyridin-4-amine Chemical compound NC1=CC=NC=C1Cl KJBKPRMEMJKXDV-UHFFFAOYSA-N 0.000 description 1
- GPMHHELOMRCBRN-UHFFFAOYSA-N 3-methoxypyridin-4-amine Chemical compound COC1=CN=CC=C1N GPMHHELOMRCBRN-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JAIYUIOGVNRXEW-UHFFFAOYSA-N 4-aminopyrimidine-5-carbonitrile Chemical compound NC1=NC=NC=C1C#N JAIYUIOGVNRXEW-UHFFFAOYSA-N 0.000 description 1
- VJJXGBODRUXZAZ-UHFFFAOYSA-N 4-bromo-7-methoxy-2-(4-methoxy-1-methylpiperidin-4-yl)furo[2,3-c]pyridine Chemical compound O1C=2C(OC)=NC=C(Br)C=2C=C1C1(OC)CCN(C)CC1 VJJXGBODRUXZAZ-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- YJUYPLVLAHBYCM-UHFFFAOYSA-N 7-chlorofuro[2,3-c]pyridine Chemical compound ClC1=NC=CC2=C1OC=C2 YJUYPLVLAHBYCM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000670727 Amida Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- ZOTXWVXWVSLXTC-UHFFFAOYSA-N COC1=C(C=CN=C1)NC(=O)C2=CC=NC=C2 Chemical compound COC1=C(C=CN=C1)NC(=O)C2=CC=NC=C2 ZOTXWVXWVSLXTC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010020164 HIV infection CDC Group III Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 206010027236 Meningitis fungal Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LWTQEYQITXVPLN-UHFFFAOYSA-N N-(2,6-dichloro-4-cyanophenyl)pyridine-4-carboxamide Chemical compound ClC1=C(C(=CC(=C1)C#N)Cl)NC(=O)C1=CC=NC=C1 LWTQEYQITXVPLN-UHFFFAOYSA-N 0.000 description 1
- CEECPWRWUMQUKU-UHFFFAOYSA-N NC1=C(Cl)C=[N+]([O-])C=C1Cl Chemical compound NC1=C(Cl)C=[N+]([O-])C=C1Cl CEECPWRWUMQUKU-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- FKDWIMIRRGGDDE-UHFFFAOYSA-N [N].CCN(CC)CC Chemical compound [N].CCN(CC)CC FKDWIMIRRGGDDE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- OJKBCQOJVMAHDX-UHFFFAOYSA-N diethyl(pyridin-3-yl)borane Chemical compound CCB(CC)C1=CC=CN=C1 OJKBCQOJVMAHDX-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 201000010056 fungal meningitis Diseases 0.000 description 1
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical class C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- PVVWWBJGKHSPJG-UHFFFAOYSA-N n-(2,6-difluorophenyl)pyridine-4-carboxamide Chemical compound FC1=CC=CC(F)=C1NC(=O)C1=CC=NC=C1 PVVWWBJGKHSPJG-UHFFFAOYSA-N 0.000 description 1
- JNVIIHPWPKHZAP-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-7-methoxy-2-(methoxymethyl)furo[2,3-c]pyridine-4-carboxamide Chemical compound C1=NC(OC)=C2OC(COC)=CC2=C1C(=O)NC1=C(Cl)C=NC=C1Cl JNVIIHPWPKHZAP-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- JLPJFSCQKHRSQR-UHFFFAOYSA-N oxolan-3-one Chemical compound O=C1CCOC1 JLPJFSCQKHRSQR-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical class [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000005496 tempering Methods 0.000 description 1
- KUYMVWXKHQSIAS-UHFFFAOYSA-N tert-butyl 2-chloroacetate Chemical group CC(C)(C)OC(=O)CCl KUYMVWXKHQSIAS-UHFFFAOYSA-N 0.000 description 1
- TUAURSGTWAJPOW-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(7-methoxyfuro[2,3-c]pyridin-2-yl)piperidine-1-carboxylate Chemical compound O1C=2C(OC)=NC=CC=2C=C1C1(O)CCN(C(=O)OC(C)(C)C)CC1 TUAURSGTWAJPOW-UHFFFAOYSA-N 0.000 description 1
- XZRMCGIXQJVUSZ-UHFFFAOYSA-N tert-butyl 4-methoxy-4-(7-methoxyfuro[2,3-c]pyridin-2-yl)piperidine-1-carboxylate Chemical compound O1C=2C(OC)=NC=CC=2C=C1C1(OC)CCN(C(=O)OC(C)(C)C)CC1 XZRMCGIXQJVUSZ-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 229940124788 therapeutic inhibitor Drugs 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000008009 topical excipient Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9812322 | 1998-06-08 | ||
| GBGB9812322.7A GB9812322D0 (en) | 1998-06-08 | 1998-06-08 | Benzofurans and their therapeutic use |
| GBGB9820768.1A GB9820768D0 (en) | 1998-09-23 | 1998-09-23 | Heterocyclic compounds and their therapeutic use |
| GB9820768 | 1998-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2204171T3 true ES2204171T3 (es) | 2004-04-16 |
Family
ID=26313823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99955472T Expired - Lifetime ES2204171T3 (es) | 1998-06-08 | 1999-06-07 | Derivados de furopiridina y su utilizacion terapeutica. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6169090B1 (enExample) |
| EP (1) | EP1086106B1 (enExample) |
| JP (1) | JP2003526601A (enExample) |
| AT (1) | ATE247660T1 (enExample) |
| AU (1) | AU753897B2 (enExample) |
| CA (1) | CA2333629A1 (enExample) |
| CO (1) | CO5080802A1 (enExample) |
| DE (1) | DE69910568T2 (enExample) |
| ES (1) | ES2204171T3 (enExample) |
| PE (1) | PE20000734A1 (enExample) |
| TW (1) | TW555759B (enExample) |
| WO (1) | WO1999064423A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000038683A1 (en) * | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | THROMBIN OR FACTOR Xa INHIBITORS |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| GB0003256D0 (en) | 2000-02-11 | 2000-04-05 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
| WO2002012189A1 (en) * | 2000-08-09 | 2002-02-14 | Mitsubishi Pharma Corporation | Fused bicyclic amide compounds and medicinal use thereof |
| US8176296B2 (en) | 2000-10-26 | 2012-05-08 | Cypress Semiconductor Corporation | Programmable microcontroller architecture |
| US6724220B1 (en) | 2000-10-26 | 2004-04-20 | Cyress Semiconductor Corporation | Programmable microcontroller architecture (mixed analog/digital) |
| US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
| EP1621196A4 (en) * | 2003-03-17 | 2007-03-21 | Kyowa Hakko Kogyo Kk | THERAPEUTIC AND / OR PREVENTIVE AGENT FOR CHRONIC SKIN DISEASES |
| DE10318610A1 (de) * | 2003-04-24 | 2004-11-11 | Elbion Ag | 7-Azaindole und deren Verwendung als Therapeutika |
| US8069436B2 (en) | 2004-08-13 | 2011-11-29 | Cypress Semiconductor Corporation | Providing hardware independence to automate code generation of processing device firmware |
| JP5878327B2 (ja) * | 2011-10-12 | 2016-03-08 | 花王株式会社 | 手洗い用食器洗浄剤組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| AU675680B2 (en) | 1992-10-14 | 1997-02-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| DK0672031T3 (da) | 1992-12-02 | 2003-06-10 | Pfizer | Catecholdiethere som selektive PDE IV-inhibitorer |
| EP0637586B1 (en) | 1993-08-05 | 1999-06-02 | HOECHST MARION ROUSSEL, Inc. | 2-(Piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)-benzofuran-7-carbamate derivatives, their preparation and their use as acetylcholinesterase inhibitors |
| JPH07267961A (ja) * | 1994-03-30 | 1995-10-17 | Taisho Pharmaceut Co Ltd | ベンゾフロ［３，２−ｄピリミジン−４−オン誘導体 |
| WO1996036638A1 (en) | 1995-05-19 | 1996-11-21 | Chiroscience Limited | Xanthines and their therapeutic use |
| JPH09108832A (ja) | 1995-10-19 | 1997-04-28 | Mitsubishi Electric Corp | 溶接構造体およびその溶接方法 |
| JP2000501411A (ja) * | 1995-12-05 | 2000-02-08 | ダーウィン・ディスカバリー・リミテッド | ベンゾフランカルボキサミドおよびスルホンアミド |
| DE69717277T2 (de) * | 1996-05-15 | 2003-09-18 | Altana Pharma Ag | Imidazopyridine |
| HUP0100042A3 (en) * | 1996-05-20 | 2003-01-28 | Darwin Discovery Ltd Cambridge | Benzofuran carboxamides medicaments containing the same and their therapeutic use |
| ES2188983T4 (es) * | 1996-08-19 | 2004-06-01 | Altana Pharma Ag | Nuevas benzofuran-4-carboxamidas. |
| JP4166296B2 (ja) | 1997-04-25 | 2008-10-15 | 塩野義製薬株式会社 | ドーパミン受容体拮抗作用を有する化合物 |
-
1999
- 1999-06-03 TW TW088109174A patent/TW555759B/zh active
- 1999-06-07 CA CA002333629A patent/CA2333629A1/en not_active Abandoned
- 1999-06-07 DE DE69910568T patent/DE69910568T2/de not_active Expired - Fee Related
- 1999-06-07 WO PCT/GB1999/001791 patent/WO1999064423A1/en not_active Ceased
- 1999-06-07 JP JP2000553432A patent/JP2003526601A/ja active Pending
- 1999-06-07 AT AT99955472T patent/ATE247660T1/de not_active IP Right Cessation
- 1999-06-07 AU AU42776/99A patent/AU753897B2/en not_active Ceased
- 1999-06-07 EP EP99955472A patent/EP1086106B1/en not_active Expired - Lifetime
- 1999-06-07 ES ES99955472T patent/ES2204171T3/es not_active Expired - Lifetime
- 1999-06-08 CO CO99035782A patent/CO5080802A1/es unknown
- 1999-06-08 US US09/328,182 patent/US6169090B1/en not_active Expired - Fee Related
- 1999-06-08 PE PE1999000510A patent/PE20000734A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69910568D1 (de) | 2003-09-25 |
| DE69910568T2 (de) | 2004-06-17 |
| WO1999064423A1 (en) | 1999-12-16 |
| AU4277699A (en) | 1999-12-30 |
| JP2003526601A (ja) | 2003-09-09 |
| CA2333629A1 (en) | 1999-12-16 |
| AU753897B2 (en) | 2002-10-31 |
| CO5080802A1 (es) | 2001-09-25 |
| PE20000734A1 (es) | 2000-08-18 |
| TW555759B (en) | 2003-10-01 |
| US6169090B1 (en) | 2001-01-02 |
| EP1086106A1 (en) | 2001-03-28 |
| ATE247660T1 (de) | 2003-09-15 |
| EP1086106B1 (en) | 2003-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2162467C2 (ru) | Карбоксамиды бензофурана и их фармацевтическая композиция | |
| RU2170730C2 (ru) | Хинолиновые карбоксамиды и фармацевтическая композиция на их основе | |
| US6069151A (en) | Quinolines and their therapeutic use | |
| AU2012312305B2 (en) | Acyclic cyanoethylpyrazoles as janus kinase inhibitors | |
| ES2200163T3 (es) | Aril-carboxamidas biciclicas y su utilizacion terapeutica. | |
| AU2014234906B2 (en) | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | |
| EP0946541B1 (en) | Quinolines and their therapeutic use | |
| US5773467A (en) | Benzofuran sulphonanmides | |
| AU2014234909B2 (en) | Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors | |
| JPH08502741A (ja) | ５−ｈｔ▲下４▼レセプターアンタゴニスト用のピペリジン誘導体 | |
| WO2016061751A1 (en) | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors | |
| ES2231439T3 (es) | Derivados benzooxazol como inhibidores de tnf y de pde iv. | |
| US6169090B1 (en) | Heterocyclic compounds and their therapeutic use | |
| US5792774A (en) | Quinolones and their therapeutic use | |
| US6066657A (en) | Benzofuran-4-carboxamides and their therapeutic use | |
| KR20000011120A (ko) | 벤조퓨란카르복사미드 및 이들의 치료학적 용도 |